Cancer and its treatments can lead to an increase in bone remodeling, increasing the risk of developing osteoporosis. Endocrine therapies for breast and prostate cancer in particular have an adverse effect on bone, but patients with other solid tumors or hematologic diseases often have a significantly increased osteologic risk profile as well. At the same time, long-term antiresorptive therapy, as used to treat bone metastases or osteoporosis, increases the risk of side effects such as osteonecrosis of the jaw or atypical fractures.
The National Center for Tumor Diseases Dresden (NCT/UCC), in collaboration with the Department of Endocrinology of Medical Clinic 3, offers appropriate advice to patients in its Bone Health and Cancer consultations.
The consultation includes an anamnestic risk assessment, which is supplemented by laboratory diagnostics and/or a bone density scan, in order to assess the individual risk of affected patients and to be able to make a therapy recommendation or, if necessary, to initiate bone protection therapy.
Patients with borderline or complex findings and a high osteological risk will benefit particularly from this special offer.
